Biosimilar Versus Urinary Gonadotropins (BEMDON)
Infertility
About this trial
This is an interventional treatment trial for Infertility focused on measuring Biosimilar, ovarian stimulation, oocyte donor
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18-35 years who meet the criteria for entry into the oocyte donor program and that are going to undergo controlled ovarian stimulation
Exclusion Criteria:
- Patient with a basal antral count> 20 follicles in total or <6 antral follicles per ovary
- Patients with comorbidities that, in the opinion of the investigator, may interfere with the treatment of ovarian stimulation
- The presence of ovarian cysts that judgment of the investigator would interfere with the stimulation or may pose a risk to the donor
- BMI <18 kg / m2
- BMI> 30 kg / m2
- Severe hypersensitivity to drugs with similar structure
Sites / Locations
- IVI Madrid
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Biosimilar recombinant FSH
Urinary FSH
Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation